VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia® in Adolescents
-Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need- CAMPBELL, Calif. , March 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced
View HTML
Toggle Summary VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream
- VIVUS to Receive Milestone Payment from Alvogen ; Significant Worldwide Growth Potential for Qsymia - CAMPBELL, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that its Korean marketing partner, Alvogen , has
View HTML
Toggle Summary VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020
CAMPBELL, Calif. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter of 2019 after the market close on Tuesday, March 3, 2020 . The company will host a conference call with
View HTML
Toggle Summary VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life
CAMPBELL, Calif. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration ( FDA ) has approved the supplemental New Drug Application (sNDA) for an improved formulation of PANCREAZE ®
View HTML
Toggle Summary New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Weight Management Tool
-Data published in Journal of General Internal Medicine show that patients using Qsymia and other weight loss tools, lost at least 5% of body weight loss compared with those not using Qsymia- CAMPBELL, Calif. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc.
View HTML
Toggle Summary VIVUS to Present at Biotech Showcase on January 13, 2020
CAMPBELL, Calif. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos , Chief Executive Officer, will present at the Biotech Showcase™ 2020 on Monday, January 13, 2020 at 3:30 pm PT / 6:30pm ET .
View HTML
Toggle Summary VIVUS Adopts Stockholder Rights Plan
CAMPBELL, Calif. , Dec. 31, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors adopted a new stockholder rights plan to replace the Company’s stockholder rights plan that expired in
View HTML
Toggle Summary VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity
-Data published in Diabetes, Obesity and Metabolism demonstrate that Qsymia provides statistically significant weight loss compared with placebo over an 8 week period, provide basis for ongoing 56 week phase 4 study in obese adolescents- CAMPBELL, Calif. , Dec.
View HTML
Toggle Summary VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on December 3, 2019
CAMPBELL, Calif. , Nov. 25, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos , Chief Executive Officer at VIVUS , will present at the Piper Jaffray 31st Annual Healthcare Conference at 1:10 P.M.
View HTML
Toggle Summary New Clinical Data Demonstrate VIVUS’ Qsymia® is Effective at Reducing Binge Eating in Patients with Binge-Eating Disorder or Bulimia Nervosa
-Data published in International Journal of Eating Disorders show patients in the Qsymia group had 75% decrease in binge day frequency compared with 19% for placebo- CAMPBELL, Calif. , Nov. 20, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today
View HTML